메뉴 건너뛰기




Volumn 64, Issue 1, 2004, Pages 27-44

First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PEMETREXED; RALTITREXED; UFT;

EID: 1642492868     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464010-00003     Document Type: Review
Times cited : (24)

References (117)
  • 1
    • 0035467993 scopus 로고    scopus 로고
    • Global cancer statistics in the year 2000
    • Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2 (9): 533-43
    • (2001) Lancet Oncol , vol.2 , Issue.9 , pp. 533-543
    • Parkin, D.M.1
  • 3
    • 1642468240 scopus 로고    scopus 로고
    • Long term survivors of metastatic colorectal cancer treated with chemotherapy only: A North Central Cancer Treatment Group review
    • abstract no. 693
    • Hobday TJ, Cha SS, Sargent DJ, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a North Central Cancer Treatment Group review [abstract no. 693]. Proc Am Soc Clin Oncol 2002; 21
    • (2002) Proc Am Soc Clin Oncol , vol.21
    • Hobday, T.J.1    Cha, S.S.2    Sargent, D.J.3
  • 5
    • 0027461840 scopus 로고
    • Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
    • Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306 (6880): 752-5
    • (1993) BMJ , vol.306 , Issue.6880 , pp. 752-755
    • Scheithauer, W.1    Rosen, H.2    Kornek, G.V.3
  • 6
    • 0028945766 scopus 로고
    • Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer
    • Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6 (3): 267-74
    • (1995) Ann Oncol , vol.6 , Issue.3 , pp. 267-274
    • Glimelius, B.1    Hoffman, K.2    Graf, W.3
  • 7
    • 0034596549 scopus 로고    scopus 로고
    • Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis: Colorectal Cancer Collaborative Group
    • Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis: Colorectal Cancer Collaborative Group. BMJ 2000; 321 (7260): 531-5
    • (2000) BMJ , vol.321 , Issue.7260 , pp. 531-535
    • Simmonds, P.C.1
  • 8
    • 33745464490 scopus 로고
    • Fluorinated pyrimidines: A new class of tumor inhibitory compounds
    • Heidelberger C, Chanakar NK, Danenberg PV, et al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 1957; 179: 663-6
    • (1957) Nature , vol.179 , pp. 663-666
    • Heidelberger, C.1    Chanakar, N.K.2    Danenberg, P.V.3
  • 9
    • 0026721532 scopus 로고
    • Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate: Advanced Colorectal Cancer Meta-Analysis Project
    • Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10 (6): 896-903
    • (1992) J Clin Oncol , vol.10 , Issue.6 , pp. 896-903
  • 10
    • 0024347268 scopus 로고
    • Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
    • Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7 (10): 1407-18
    • (1989) J Clin Oncol , vol.7 , Issue.10 , pp. 1407-1418
    • Poon, M.A.1    O'Connell, M.J.2    Moertel, C.G.3
  • 11
    • 33947093786 scopus 로고
    • Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism
    • Danenberg PV, Danenberg KD. Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978; 17: 4018-24
    • (1978) Biochemistry , vol.17 , pp. 4018-4024
    • Danenberg, P.V.1    Danenberg, K.D.2
  • 12
    • 0026006962 scopus 로고
    • Biochemical modulation of fluorouracil with leucovorin: Confimratory evidence of improved therapeutic efficacy in advanced colorectal cancer
    • Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confimratory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9 (11): 1967-72
    • (1991) J Clin Oncol , vol.9 , Issue.11 , pp. 1967-1972
    • Poon, M.A.1    O'Connell, M.J.2    Wieand, H.S.3
  • 13
    • 1642508983 scopus 로고    scopus 로고
    • Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-anaysis based on 2,571 patients
    • abstract no. 1180
    • Piedbois P, Michiels S, for the Meta-Analysis Group in Cancer: survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated meta-anaysis based on 2,571 patients [abstract no. 1180]. Proc Am Soc Clin Oncol 2003; 22: 294
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 294
    • Piedbois, P.1    Michiels, S.2
  • 14
    • 0030931974 scopus 로고    scopus 로고
    • A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    • Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer 1997; 80 (7): 1179-87
    • (1997) Cancer , vol.80 , Issue.7 , pp. 1179-1187
    • Machover, D.1
  • 15
    • 0029813416 scopus 로고    scopus 로고
    • Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial: Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1
    • Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial: Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996; 14 (8): 2274-9
    • (1996) J Clin Oncol , vol.14 , Issue.8 , pp. 2274-2279
    • Jager, E.1    Heike, M.2    Bernhard, H.3
  • 16
    • 0028175144 scopus 로고
    • Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
    • Buroker TR, O'Connell M, Wieand HS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14-20
    • (1994) J Clin Oncol , vol.12 , pp. 14-20
    • Buroker, T.R.1    O'Connell, M.2    Wieand, H.S.3
  • 17
    • 0028219974 scopus 로고
    • Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer: Advanced Colorectal Cancer Meta-Analysis Project
    • Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994; 12 (5): 960-9
    • (1994) J Clin Oncol , vol.12 , Issue.5 , pp. 960-969
  • 18
    • 0027520967 scopus 로고
    • Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in paients with advanced symptomatic colorectal cancer: The Nordic Gastrointestinal Tumor Adjuvant Therapy Group
    • Glimelius B. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in paients with advanced symptomatic colorectal cancer: the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Ann Oncol 1993; 4 (3): 235-40
    • (1993) Ann Oncol , vol.4 , Issue.3 , pp. 235-240
    • Glimelius, B.1
  • 19
    • 0026642174 scopus 로고
    • Leucovorin enhances cytotoxicity of tremetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells
    • Romanini A, Li WW, Colofiore JR, et al. Leucovorin enhances cytotoxicity of tremetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. J Natl Cancer Inst 1992; 84: 1033-8
    • (1992) J Natl Cancer Inst , vol.84 , pp. 1033-1038
    • Romanini, A.1    Li, W.W.2    Colofiore, J.R.3
  • 20
    • 0031056423 scopus 로고    scopus 로고
    • Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer
    • Blanke CD, Kasimis B, Schein P, et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997; 15: 915-20
    • (1997) J Clin Oncol , vol.15 , pp. 915-920
    • Blanke, C.D.1    Kasimis, B.2    Schein, P.3
  • 21
    • 0036227995 scopus 로고    scopus 로고
    • A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
    • Blanke CD, Shultz J, Cox J, et al. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol 2002; 13 (1): 87-91
    • (2002) Ann Oncol , vol.13 , Issue.1 , pp. 87-91
    • Blanke, C.D.1    Shultz, J.2    Cox, J.3
  • 22
    • 0036231984 scopus 로고    scopus 로고
    • Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: Final results of a randomised European study
    • Punt CJ, Keizer HJ, Douma J, et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 2002; 13 (1): 81-6
    • (2002) Ann Oncol , vol.13 , Issue.1 , pp. 81-86
    • Punt, C.J.1    Keizer, H.J.2    Douma, J.3
  • 23
    • 0017177398 scopus 로고
    • Pharmacokinetics of the fluoropyrimidines: Implications for their clinical use
    • Myers CE, Diasio RB, Eliot HM, et al. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. Cancer Treat Rev 1975; 3: 175-83
    • (1975) Cancer Treat Rev , vol.3 , pp. 175-183
    • Myers, C.E.1    Diasio, R.B.2    Eliot, H.M.3
  • 24
    • 0344109583 scopus 로고    scopus 로고
    • Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer: Meta-Analysis Group in Cancer
    • Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer: Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16 (1): 301-8
    • (1998) J Clin Oncol , vol.16 , Issue.1 , pp. 301-308
  • 25
    • 0026637845 scopus 로고
    • Novel mechanism (s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
    • Aschele C, Sobrero A, Faderan MA, et al. Novel mechanism (s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52 (7): 1855-64
    • (1992) Cancer Res , vol.52 , Issue.7 , pp. 1855-1864
    • Aschele, C.1    Sobrero, A.2    Faderan, M.A.3
  • 26
    • 0031019918 scopus 로고    scopus 로고
    • Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
    • de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15 (2): 808-15
    • (1997) J Clin Oncol , vol.15 , Issue.2 , pp. 808-815
    • De Gramont, A.1    Bosset, J.F.2    Milan, C.3
  • 27
    • 0024598566 scopus 로고
    • Continuous low-dose infusion of fluorouracil: Is the benefit worth the cost
    • Macdonald JS. Continuous low-dose infusion of fluorouracil: is the benefit worth the cost. J Clin Oncol 1989; 7 (4): 412-4
    • (1989) J Clin Oncol , vol.7 , Issue.4 , pp. 412-414
    • Macdonald, J.S.1
  • 28
    • 0000419696 scopus 로고    scopus 로고
    • A simplified bimonthly regimen with leucovorin and 5FU for metastatic colorectal cancer
    • abstract no. 274
    • Tournigand C, de Gramont A, Louvet C, et al. A simplified bimonthly regimen with leucovorin and 5FU for metastatic colorectal cancer [abstract no. 274]. Proc Am Soc Clin Oncol 1998; 17
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Tournigand, C.1    De Gramont, A.2    Louvet, C.3
  • 29
    • 0345403552 scopus 로고    scopus 로고
    • Effective biomodulation by leucovorin of high dose infusional fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
    • Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leucovorin of high dose infusional fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 418-26
    • (1998) J Clin Oncol , vol.16 , pp. 418-426
    • Kohne, C.H.1    Schoffski, P.2    Wilke, H.3
  • 30
    • 1642468238 scopus 로고
    • A phase III multicenter randomized study in advanced colorectal cancer: Weekly high dose continuous infusion fluorouracil versus fluorouracil plus leucovorin
    • Aranda E, Diaz-Rubio E, Cervantes A, et al. A phase III multicenter randomized study in advanced colorectal cancer: weekly high dose continuous infusion fluorouracil versus fluorouracil plus leucovorin. Ann Oncol 1988; 9: 727-31
    • (1988) Ann Oncol , vol.9 , pp. 727-731
    • Aranda, E.1    Diaz-Rubio, E.2    Cervantes, A.3
  • 31
    • 0024539308 scopus 로고
    • A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
    • Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32
    • (1989) J Clin Oncol , vol.7 , pp. 425-432
    • Lokich, J.J.1    Ahlgren, J.D.2    Gullo, J.J.3
  • 32
    • 0032127244 scopus 로고    scopus 로고
    • Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
    • Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-81
    • (1998) Eur J Cancer , vol.34 , pp. 1274-1281
    • Miwa, M.1    Ura, M.2    Nishida, M.3
  • 33
    • 0035871538 scopus 로고    scopus 로고
    • Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    • Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19 (8): 2282-92
    • (2001) J Clin Oncol , vol.19 , Issue.8 , pp. 2282-2292
    • Hoff, P.M.1    Ansari, R.2    Batist, G.3
  • 34
    • 0035503151 scopus 로고    scopus 로고
    • Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
    • Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19 (21): 4097-106
    • (2001) J Clin Oncol , vol.19 , Issue.21 , pp. 4097-4106
    • Van Cutsem, E.1    Twelves, C.2    Cassidy, J.3
  • 35
    • 0036731818 scopus 로고    scopus 로고
    • Multicenter phase III study of uracil/tegafur and oral leucovin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
    • Douillard JY, Hoff PM, Skillings J, et al. Multicenter phase III study of uracil/tegafur and oral leucovin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20 (17): 3605-16
    • (2002) J Clin Oncol , vol.20 , Issue.17 , pp. 3605-3616
    • Douillard, J.Y.1    Hoff, P.M.2    Skillings, J.3
  • 36
    • 0036727089 scopus 로고    scopus 로고
    • Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucorin in patients with previously untreated metastatic colorectal cancer
    • Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20 (17): 3617-27
    • (2002) J Clin Oncol , vol.20 , Issue.17 , pp. 3617-3627
    • Carmichael, J.1    Popiela, T.2    Radstone, D.3
  • 37
    • 0033774136 scopus 로고    scopus 로고
    • Preclinical development of eniluracil: Enhancing the therapeutic index and dosing convenience of 5-fluorouracil
    • Paff M, Baccanari D, Davis ST, et al. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil. Invest New Drugs 2000; 18: 365-71
    • (2000) Invest New Drugs , vol.18 , pp. 365-371
    • Paff, M.1    Baccanari, D.2    Davis, S.T.3
  • 38
    • 0003300519 scopus 로고    scopus 로고
    • International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous 5-FU plus LV in the treatment of advanced colorectal cancer
    • abstract no. 523
    • Van Cutsem E, Sorensen JI, Cassidy J, et al. International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous 5-FU plus LV in the treatment of advanced colorectal cancer [abstract no. 523]. Proc Am Soc Clin Oncol 2001; 20
    • (2001) Proc Am Soc Clin Oncol , vol.20
    • Van Cutsem, E.1    Sorensen, J.I.2    Cassidy, J.3
  • 39
    • 18244414936 scopus 로고    scopus 로고
    • Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
    • van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18 (14): 2772-9
    • (2000) J Clin Oncol , vol.18 , Issue.14 , pp. 2772-2779
    • Van Groeningen, C.J.1    Peters, G.J.2    Schornagel, J.H.3
  • 40
    • 0037430037 scopus 로고    scopus 로고
    • EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
    • Van den Brande J, Schoffski P, Schellens JH, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88 (5): 648-53
    • (2003) Br J Cancer , vol.88 , Issue.5 , pp. 648-653
    • Van Den Brande, J.1    Schoffski, P.2    Schellens, J.H.3
  • 41
    • 9044245305 scopus 로고    scopus 로고
    • ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
    • Zalcberg JR, Cunningham D, van Cutsem E. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14: 716-21
    • (1996) J Clin Oncol , vol.14 , pp. 716-721
    • Zalcberg, J.R.1    Cunningham, D.2    Van Cutsem, E.3
  • 42
    • 5544237608 scopus 로고    scopus 로고
    • Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer: 'Tomudex' Colorectal Cancer Study Group
    • Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer: 'Tomudex' Colorectal Cancer Study Group. Ann Oncol 1996; 7 (9): 961-5
    • (1996) Ann Oncol , vol.7 , Issue.9 , pp. 961-965
    • Cunningham, D.1    Zalcberg, J.R.2    Rath, U.3
  • 43
    • 0031671255 scopus 로고    scopus 로고
    • Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer: Tomudex Colorectal Cancer Study Group
    • Cocconi G, Cunningham D, van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer: Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16: 2943-52
    • (1998) J Clin Oncol , vol.16 , pp. 2943-2952
    • Cocconi, G.1    Cunningham, D.2    Van Cutsem, E.3
  • 44
    • 0031888857 scopus 로고    scopus 로고
    • Mature results from three large controlled studies with raltirexted ('Tomudex')
    • Cunningham D. Mature results from three large controlled studies with raltirexted ('Tomudex'). Br J Cancer 1998; 77 Suppl. 2: 15-21
    • (1998) Br J Cancer , vol.77 , Issue.2 SUPPL. , pp. 15-21
    • Cunningham, D.1
  • 45
    • 0033589526 scopus 로고    scopus 로고
    • Safety of raltitrexed
    • Ford HER, Cunningham D. Safety of raltitrexed. Lancet 1999; 354: 1824-5
    • (1999) Lancet , vol.354 , pp. 1824-1825
    • Ford, H.E.R.1    Cunningham, D.2
  • 46
    • 0002639092 scopus 로고    scopus 로고
    • Qualitative and chronological assessment of toxicities during treatment with raltitrexed (Tomudex) in 861 patients: Implications for patient management
    • abstract no. 222
    • Garcia-Vargas JE, Sahmoud T, Smith MP, et al. Qualitative and chronological assessment of toxicities during treatment with raltitrexed (Tomudex) in 861 patients: implications for patient management [abstract no. 222]. Eur J Cancer 1999; 35 Suppl. 4: S72
    • (1999) Eur J Cancer , vol.35 , Issue.4 SUPPL.
    • Garcia-Vargas, J.E.1    Sahmoud, T.2    Smith, M.P.3
  • 47
    • 0037018765 scopus 로고    scopus 로고
    • Comparison of survival, palliation, and quality of life with three chemotherapy regiments in metastatic colorectal cancer: A multicentre randomised trial
    • Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regiments in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359: 1555-63
    • (2002) Lancet , vol.359 , pp. 1555-1563
    • Maughan, T.S.1    James, R.D.2    Kerr, D.J.3
  • 48
    • 34548470595 scopus 로고    scopus 로고
    • Drug-company decision to end cancer trial
    • Drug-company decision to end cancer trial [editorial]. Lancet 1999; 354: 1045
    • (1999) Lancet , vol.354 , pp. 1045
  • 49
    • 0032693973 scopus 로고    scopus 로고
    • Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
    • Cripps C, Burnell M, Jolivet J, et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999; 10 (10): 1175-9
    • (1999) Ann Oncol , vol.10 , Issue.10 , pp. 1175-1179
    • Cripps, C.1    Burnell, M.2    Jolivet, J.3
  • 50
    • 0034655141 scopus 로고    scopus 로고
    • Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study
    • John W, Picus J, Blanke CD, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000; 88 (8): 1807-13
    • (2000) Cancer , vol.88 , Issue.8 , pp. 1807-1813
    • John, W.1    Picus, J.2    Blanke, C.D.3
  • 51
    • 0029029436 scopus 로고
    • Topoisomerase I related parameters and camptothecin activity in the colon carcinoma cell lines from the national cancer institute anticancer screen
    • Goldwasser F, Bae I, Valentini M, et al. Topoisomerase I related parameters and camptothecin activity in the colon carcinoma cell lines from the national cancer institute anticancer screen. Cancer Res 1995; 55: 2116-21
    • (1995) Cancer Res , vol.55 , pp. 2116-2121
    • Goldwasser, F.1    Bae, I.2    Valentini, M.3
  • 52
    • 0029758307 scopus 로고    scopus 로고
    • Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity
    • McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996; 74: 508-12
    • (1996) Br J Cancer , vol.74 , pp. 508-512
    • McLeod, H.L.1    Keith, W.N.2
  • 53
    • 0028033906 scopus 로고
    • Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors
    • Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12: 530-42
    • (1994) Cancer Invest , vol.12 , pp. 530-542
    • Pommier, Y.1    Leteurtre, F.2    Fesen, M.R.3
  • 54
    • 0003293866 scopus 로고    scopus 로고
    • High thymidylate expression does not preclude activity of CPT-11 in colon cancer
    • abstract no. 1080
    • Saltz L, Danenberg K, Paty BP, et al. High thymidylate expression does not preclude activity of CPT-11 in colon cancer [abstract no. 1080]. Proc Am Soc Clin Oncol 1998; 17
    • (1998) Proc Am Soc Clin Oncol , vol.17
    • Saltz, L.1    Danenberg, K.2    Paty, B.P.3
  • 55
    • 0029741368 scopus 로고    scopus 로고
    • Involvement of β-glucuoronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivativeirinotecan hydrochloride (CPT-11) in rats
    • Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of β-glucuoronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivativeirinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-7
    • (1996) Cancer Res , vol.56 , pp. 3752-3757
    • Takasuna, K.1    Hagiwara, T.2    Hirohashi, M.3
  • 56
    • 0031014627 scopus 로고    scopus 로고
    • Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
    • Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15 (1): 251-60
    • (1997) J Clin Oncol , vol.15 , Issue.1 , pp. 251-260
    • Rougier, P.1    Bugat, R.2    Douillard, J.Y.3
  • 57
    • 0032585197 scopus 로고    scopus 로고
    • Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
    • Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1407-12
    • (1998) Lancet , vol.352 , Issue.9138 , pp. 1407-1412
    • Rougier, P.1    Van Cutsem, E.2    Bajetta, E.3
  • 58
    • 0032585232 scopus 로고    scopus 로고
    • Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    • Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1413-8
    • (1998) Lancet , vol.352 , Issue.9138 , pp. 1413-1418
    • Cunningham, D.1    Pyrhonen, S.2    James, R.D.3
  • 59
    • 0029919598 scopus 로고    scopus 로고
    • Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
    • Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14 (3): 709-15
    • (1996) J Clin Oncol , vol.14 , Issue.3 , pp. 709-715
    • Conti, J.A.1    Kemeny, N.E.2    Saltz, L.B.3
  • 60
    • 0030818926 scopus 로고    scopus 로고
    • Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
    • Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15 (8): 2910-9
    • (1997) J Clin Oncol , vol.15 , Issue.8 , pp. 2910-2919
    • Pitot, H.C.1    Wender, D.B.2    O'Connell, M.J.3
  • 61
    • 0033198035 scopus 로고    scopus 로고
    • CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
    • GERCOR
    • Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35 (9): 1343-7
    • (1999) Eur J Cancer , vol.35 , Issue.9 , pp. 1343-1347
    • Andre, T.1    Louvet, C.2    Maindrault-Goebel, F.3
  • 62
    • 0034727063 scopus 로고    scopus 로고
    • Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
    • Irinotecan Study Group
    • Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343 (13): 905-14
    • (2000) N Engl J Med , vol.343 , Issue.13 , pp. 905-914
    • Saltz, L.B.1    Cox, J.V.2    Blanke, C.3
  • 63
    • 0034712536 scopus 로고    scopus 로고
    • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
    • Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355 (9209): 1041-7
    • (2000) Lancet , vol.355 , Issue.9209 , pp. 1041-1047
    • Douillard, J.Y.1    Cunningham, D.2    Roth, A.D.3
  • 64
    • 0035135378 scopus 로고    scopus 로고
    • Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard
    • Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001; 6 (1): 81-91
    • (2001) Oncologist , vol.6 , Issue.1 , pp. 81-91
    • Saltz, L.B.1    Douillard, J.Y.2    Pirotta, N.3
  • 65
    • 0036895122 scopus 로고    scopus 로고
    • Early detection of toxicity and adjustment of ongoing clinical trials: The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program
    • Goldberg RM, Sargent DJ, Morton RF, et al. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol 2002; 20 (23): 4591-6
    • (2002) J Clin Oncol , vol.20 , Issue.23 , pp. 4591-4596
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3
  • 66
    • 0035849938 scopus 로고    scopus 로고
    • Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
    • Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345 (2): 144-5
    • (2001) N Engl J Med , vol.345 , Issue.2 , pp. 144-145
    • Sargent, D.J.1    Niedzwiecki, D.2    O'Connell, M.J.3
  • 67
    • 0035884212 scopus 로고    scopus 로고
    • Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel
    • Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19 (18): 3801-7
    • (2001) J Clin Oncol , vol.19 , Issue.18 , pp. 3801-3807
    • Rothenberg, M.L.1    Meropol, N.J.2    Poplin, E.A.3
  • 68
    • 0024373787 scopus 로고
    • Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): New experimental data
    • Tashiro T, Kawada Y, Sakurai Y, et al. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): new experimental data. Biomed Pharmacother 1989; 43 (4): 251-60
    • (1989) Biomed Pharmacother , vol.43 , Issue.4 , pp. 251-260
    • Tashiro, T.1    Kawada, Y.2    Sakurai, Y.3
  • 69
    • 0024407292 scopus 로고
    • Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
    • Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989; 43 (4): 237-50
    • (1989) Biomed Pharmacother , vol.43 , Issue.4 , pp. 237-250
    • Mathe, G.1    Kidani, Y.2    Segiguchi, M.3
  • 70
    • 0031864830 scopus 로고    scopus 로고
    • Oxaliplatin: Mechanism of action and antineoplastic activity
    • Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25 (2 Suppl. 5): 4-12
    • (1998) Semin Oncol , vol.25 , Issue.2 SUPPL. 5 , pp. 4-12
    • Raymond, E.1    Faivre, S.2    Woynarowski, J.M.3
  • 71
    • 0037010085 scopus 로고    scopus 로고
    • Oxaliplatin-related side effects: Characteristics and management
    • Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29 (5 Suppl. 15): 11-20
    • (2002) Semin Oncol , vol.29 , Issue.5 SUPPL. 15 , pp. 11-20
    • Cassidy, J.1    Misset, J.L.2
  • 72
    • 0037010088 scopus 로고    scopus 로고
    • Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures
    • Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29 (5 Suppl. 15): 21-33
    • (2002) Semin Oncol , vol.29 , Issue.5 SUPPL. 15 , pp. 21-33
    • Gamelin, E.1    Gamelin, L.2    Bossi, L.3
  • 73
    • 0025020085 scopus 로고
    • Phase I study of oxaliplatin in patients with advanced cancer
    • Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25 (4): 299-303
    • (1990) Cancer Chemother Pharmacol , vol.25 , Issue.4 , pp. 299-303
    • Extra, J.M.1    Espie, M.2    Calvo, F.3
  • 74
    • 0022910291 scopus 로고
    • A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP)
    • Mathe G, Kidani Y, Triana K, et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP). Biomed Pharmacother 1986; 40 (10): 372-6
    • (1986) Biomed Pharmacother , vol.40 , Issue.10 , pp. 372-376
    • Mathe, G.1    Kidani, Y.2    Triana, K.3
  • 75
    • 0031840201 scopus 로고    scopus 로고
    • Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer
    • Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25 (2 Suppl. 5): 23-31
    • (1998) Semin Oncol , vol.25 , Issue.2 SUPPL. 5 , pp. 23-31
    • Becouarn, Y.1    Rougier, P.2
  • 76
    • 0004700371 scopus 로고    scopus 로고
    • Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
    • Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9 (1): 105-8
    • (1998) Ann Oncol , vol.9 , Issue.1 , pp. 105-108
    • Diaz-Rubio, E.1    Sastre, J.2    Zaniboni, A.3
  • 77
    • 0012797224 scopus 로고    scopus 로고
    • Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
    • Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7 (1): 95-8
    • (1996) Ann Oncol , vol.7 , Issue.1 , pp. 95-98
    • Machover, D.1    Diaz-Rubio, E.2    De Gramont, A.3
  • 78
    • 0031774842 scopus 로고    scopus 로고
    • Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
    • Andre T, Louvet C, Raymond E, et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9 (11): 1251-3
    • (1998) Ann Oncol , vol.9 , Issue.11 , pp. 1251-1253
    • Andre, T.1    Louvet, C.2    Raymond, E.3
  • 79
    • 0033874892 scopus 로고    scopus 로고
    • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    • de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16): 2938-47
    • (2000) J Clin Oncol , vol.18 , Issue.16 , pp. 2938-2947
    • De Gramont, A.1    Figer, A.2    Seymour, M.3
  • 80
    • 0033989203 scopus 로고    scopus 로고
    • Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
    • Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18 (1): 136-47
    • (2000) J Clin Oncol , vol.18 , Issue.1 , pp. 136-147
    • Giacchetti, S.1    Perpoint, B.2    Zidani, R.3
  • 81
    • 0036499136 scopus 로고    scopus 로고
    • Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer
    • Cure H, Chevalier V, Adenis A, et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2002; 20 (5): 1175-81
    • (2002) J Clin Oncol , vol.20 , Issue.5 , pp. 1175-1181
    • Cure, H.1    Chevalier, V.2    Adenis, A.3
  • 82
    • 0041055512 scopus 로고    scopus 로고
    • Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy
    • Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy. Lancet 1997; 350 (9079): 681-6
    • (1997) Lancet , vol.350 , Issue.9079 , pp. 681-686
    • Levi, F.1    Zidani, R.2    Misset, J.L.3
  • 83
    • 0037531121 scopus 로고    scopus 로고
    • Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
    • Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21 (11): 2509-069
    • (2003) J Clin Oncol , vol.21 , Issue.11 , pp. 2509-3069
    • Rothenberg, M.L.1    Oza, A.M.2    Bigelow, R.H.3
  • 84
    • 0042213493 scopus 로고    scopus 로고
    • N9741:oxaliplatin (oxal) or CPT-11 +5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT11 in advanced colorectal cancer (CRC): Updated efficacy and quality of life data from an intergroup study
    • abstract no. 1009
    • Goldberg RM, Morton RF, Sargent D, et al. N9741:oxaliplatin (oxal) or CPT-11 +5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT11 in advanced colorectal cancer (CRC): updated efficacy and quality of life data from an intergroup study [abstract no. 1009]. Proc Am Soc Clin Oncol 2003; 22: 252
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 252
    • Goldberg, R.M.1    Morton, R.F.2    Sargent, D.3
  • 85
    • 0027314411 scopus 로고
    • Microsatellite instability in cancer of the proximal colon
    • Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260 (5109): 816-9
    • (1993) Science , vol.260 , Issue.5109 , pp. 816-819
    • Thibodeau, S.N.1    Bren, G.2    Schaid, D.3
  • 86
    • 0001120708 scopus 로고    scopus 로고
    • Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer
    • Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer. Proc Am Soc Clin Oncol 2002
    • (2002) Proc Am Soc Clin Oncol
    • Grothey, A.1    Deschler, B.2    Kroening, H.3
  • 87
    • 0003226922 scopus 로고    scopus 로고
    • FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer: Final results of a phase III study
    • abstract no. 494
    • Tournigand C, Louvet C, Quinax E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer: final results of a phase III study [abstract no. 494]. Proc Am Soc Clin Oncol 2001; 21
    • (2001) Proc Am Soc Clin Oncol , vol.21
    • Tournigand, C.1    Louvet, C.2    Quinax, E.3
  • 88
    • 0025312728 scopus 로고
    • A genetic model for colorectal tumorigenesis
    • Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61 (5): 759-67
    • (1990) Cell , vol.61 , Issue.5 , pp. 759-767
    • Fearon, E.R.1    Vogelstein, B.2
  • 89
    • 0036175062 scopus 로고    scopus 로고
    • Emerging pathways in colorectal-cancer development
    • Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002; 3 (2): 83-8
    • (2002) Lancet Oncol , vol.3 , Issue.2 , pp. 83-88
    • Haydon, A.M.1    Jass, J.R.2
  • 90
    • 0034642605 scopus 로고    scopus 로고
    • Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
    • Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342 (2): 69-77
    • (2000) N Engl J Med , vol.342 , Issue.2 , pp. 69-77
    • Gryfe, R.1    Kim, H.2    Hsieh, E.T.3
  • 91
    • 0033831989 scopus 로고    scopus 로고
    • Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer
    • Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000; 87 (9): 1197-202
    • (2000) Br J Surg , vol.87 , Issue.9 , pp. 1197-1202
    • Wright, C.M.1    Dent, O.F.2    Barker, M.3
  • 92
    • 0034690610 scopus 로고    scopus 로고
    • Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
    • Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355 (9217): 1745-50
    • (2000) Lancet , vol.355 , Issue.9217 , pp. 1745-1750
    • Elsaleh, H.1    Joseph, D.2    Grieu, F.3
  • 93
    • 0038002279 scopus 로고    scopus 로고
    • Tumor microsatellite instability (MSI) status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
    • Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite instability (MSI) status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (3): 247-57
    • (2003) N Engl J Med , vol.349 , Issue.3 , pp. 247-257
    • Ribic, C.M.1    Sargent, D.J.2    Moore, M.J.3
  • 94
    • 0034087575 scopus 로고    scopus 로고
    • Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
    • Edler D, Hallstrom M, Johnston PG, et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000; 6 (4): 1378-84
    • (2000) Clin Cancer Res , vol.6 , Issue.4 , pp. 1378-1384
    • Edler, D.1    Hallstrom, M.2    Johnston, P.G.3
  • 95
    • 0036534108 scopus 로고    scopus 로고
    • Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
    • Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20 (7): 1721-8
    • (2002) J Clin Oncol , vol.20 , Issue.7 , pp. 1721-1728
    • Edler, D.1    Glimelius, B.2    Hallstrom, M.3
  • 96
    • 0030883708 scopus 로고    scopus 로고
    • Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
    • Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15 (10): 3223-9
    • (1997) J Clin Oncol , vol.15 , Issue.10 , pp. 3223-3229
    • Leichman, C.G.1    Lenz, H.J.2    Leichman, L.3
  • 97
    • 0033975032 scopus 로고    scopus 로고
    • Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients
    • Paradiso A, Simone G, Petroni S, et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000; 82 (3): 560-7
    • (2000) Br J Cancer , vol.82 , Issue.3 , pp. 560-567
    • Paradiso, A.1    Simone, G.2    Petroni, S.3
  • 98
    • 0034048729 scopus 로고    scopus 로고
    • Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
    • Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6 (4): 1322-7
    • (2000) Clin Cancer Res , vol.6 , Issue.4 , pp. 1322-1327
    • Salonga, D.1    Danenberg, K.D.2    Johnson, M.3
  • 99
    • 0035860142 scopus 로고    scopus 로고
    • A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
    • Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85 (6): 827-30
    • (2001) Br J Cancer , vol.85 , Issue.6 , pp. 827-830
    • Iacopetta, B.1    Grieu, F.2    Joseph, D.3
  • 100
    • 0035750549 scopus 로고    scopus 로고
    • Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
    • Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1 (1): 65-70
    • (2001) Pharmacogenomics J , vol.1 , Issue.1 , pp. 65-70
    • Pullarkat, S.T.1    Stoehlmacher, J.2    Ghaderi, V.3
  • 101
    • 0037144354 scopus 로고    scopus 로고
    • Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation
    • Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002; 101 (3): 253-8
    • (2002) Int J Cancer , vol.101 , Issue.3 , pp. 253-258
    • Van Kuilenburg, A.B.1    Meinsma, R.2    Zoetekouw, L.3
  • 102
    • 0034808681 scopus 로고    scopus 로고
    • Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
    • Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7 (9): 2832-9
    • (2001) Clin Cancer Res , vol.7 , Issue.9 , pp. 2832-2839
    • Raida, M.1    Schwabe, W.2    Hausler, P.3
  • 103
    • 0029973215 scopus 로고    scopus 로고
    • Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
    • Wei X, McLeod HL, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98 (3): 610-5
    • (1996) J Clin Invest , vol.98 , Issue.3 , pp. 610-615
    • Wei, X.1    McLeod, H.L.2    McMurrough, J.3
  • 104
    • 0031912432 scopus 로고    scopus 로고
    • Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
    • Lu Z, Zhang R, Carpenter JT, et al. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4 (2): 325-9
    • (1998) Clin Cancer Res , vol.4 , Issue.2 , pp. 325-329
    • Lu, Z.1    Zhang, R.2    Carpenter, J.T.3
  • 105
    • 0034892379 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
    • Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7 (8): 2182-94
    • (2001) Clin Cancer Res , vol.7 , Issue.8 , pp. 2182-2194
    • Mathijssen, R.H.1    Van Alphen, R.J.2    Verweij, J.3
  • 106
    • 0036025450 scopus 로고    scopus 로고
    • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    • Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2 (1): 43-7
    • (2002) Pharmacogenomics J , vol.2 , Issue.1 , pp. 43-47
    • Iyer, L.1    Das, S.2    Janisch, L.3
  • 107
    • 0014439920 scopus 로고
    • The natural history of primary and secondary malignant tumors of the liver 1: The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy
    • Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver 1: the prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969; 23: 198-202
    • (1969) Cancer , vol.23 , pp. 198-202
    • Bengmark, S.1    Hafstrom, L.2
  • 108
    • 0032696758 scopus 로고    scopus 로고
    • Surgical therapy of hepatic colorectal metastasis
    • Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49 (4): 231-55
    • (1999) CA Cancer J Clin , vol.49 , Issue.4 , pp. 231-255
    • Fong, Y.1
  • 109
    • 0035105338 scopus 로고    scopus 로고
    • Surgical treatment of hepatic and pulmonary metastases from colon cancer
    • Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001; 71 (3): 975-9
    • (2001) Ann Thorac Surg , vol.71 , Issue.3 , pp. 975-979
    • Headrick, J.R.1    Miller, D.L.2    Nagorney, D.M.3
  • 110
    • 1642468237 scopus 로고    scopus 로고
    • Adjuvant therapy after resection of liver-limited colorectal cancer metastases
    • Dec; San Francisco (CA)
    • Goldberg RM. Adjuvant therapy after resection of liver-limited colorectal cancer metastases. ASCO 2000 Clinical Practice Forum; 2000 Dec; San Francisco (CA); 73-7
    • (2000) ASCO 2000 Clinical Practice Forum , pp. 73-77
    • Goldberg, R.M.1
  • 111
    • 0344051547 scopus 로고    scopus 로고
    • Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer: Meta-Analysis Group in Cancer
    • Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer: Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996; 88 (5): 252-8
    • (1996) J Natl Cancer Inst , vol.88 , Issue.5 , pp. 252-258
  • 112
    • 0033619892 scopus 로고    scopus 로고
    • Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
    • Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341 (27): 2039-48
    • (1999) N Engl J Med , vol.341 , Issue.27 , pp. 2039-2048
    • Kemeny, N.1    Huang, Y.2    Cohen, A.M.3
  • 113
    • 0037087721 scopus 로고    scopus 로고
    • Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy: An intergroup study
    • Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy: an intergroup study. J Clin Oncol 2002; 20 (6): 1499-505
    • (2002) J Clin Oncol , vol.20 , Issue.6 , pp. 1499-1505
    • Kemeny, M.M.1    Adak, S.2    Gray, B.3
  • 114
    • 0032791959 scopus 로고    scopus 로고
    • Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
    • Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10 (6): 663-9
    • (1999) Ann Oncol , vol.10 , Issue.6 , pp. 663-669
    • Giacchetti, S.1    Itzhaki, M.2    Gruia, G.3
  • 115
    • 0001407135 scopus 로고    scopus 로고
    • Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
    • abstract no. 504
    • Saltz L, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [abstract no. 504]. Proc Am Soc Clin Oncol 2002; 21
    • (2002) Proc Am Soc Clin Oncol , vol.21
    • Saltz, L.1    Meropol, N.J.2    Loehrer, P.J.3
  • 116
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing Bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing Bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21 (1): 60-5
    • (2003) J Clin Oncol , vol.21 , Issue.1 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3
  • 117
    • 0043177668 scopus 로고    scopus 로고
    • Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC
    • abstract no. 3646
    • Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract no. 3646]. Proc Am Soc Clin Oncol 2003; 22
    • (2003) Proc Am Soc Clin Oncol , vol.22
    • Hurwitz, H.1    Fehrenbacher, L.2    Cartwright, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.